CD36 and Alport syndrome: Moreover, we found that ezetimibe, a cholesterol absorption inhibitor [70], which was shown to exercise a beneficial effect on dyslipidemia associated with CKD [71], inhibits the interaction between CD36 and DDR1, thus suppressing CD36-mediated fatty acid uptake and protecting from renal failure in a mouse model of Alport Syndrome in Col4a3 KO mice [68].